NeoChord Appoints Todd Berg as CEO

February 22, 2024—NeoChord, which is focused on beating heart delivery of artificial chords in the treatment of mitral valve regurgitation, announced the appointment of Todd Berg as Chief Executive Officer. Berg will oversee clinical and commercial programs for transeptal and transapical repair of damaged mitral valve chords resulting in regurgitation.

According to NeoChord, Berg has more than 30 years of experience developing and commercializing novel medical therapies and holds over 100 United States patents.

Most recently, Berg served as CEO of Metavention, an intravascular denervation company that pioneered multiorgan denervation for the treatment of type 2 diabetes and hypertension. Previously, he was CEO of Torax Medical, which developed magnetic augmentation for the treatment of gastroesophageal reflux disease. Torax was acquired by Ethicon, a division of Johnson & Johnson.

“One of the most significant clinical gaps in structural heart innovation is providing patients a treatment option to address mitral regurgitation before the disease progresses to stages where the heart becomes damaged,” commented Berg in NeoChord’s press release. “The opportunity to develop a first-line therapy for mitral valve disease, by resolving regurgitation early in the disease state, is incredibly compelling.”